Skip to main content
. 2020 Oct 6;35(44):e361. doi: 10.3346/jkms.2020.35.e361

Table 3. PET-CSF discordant cases.

Case Patient characteristics CSF biomarkers (cutoff values)
Aβ42 (667.9) t-tau (355.3) p-tau (61.8) t-tau/Aβ42 (0.641) p-tau/Aβ42 (0.103)
PET+CSF-
M/79 aMCI 777.9 305.7 63.9 0.393 0.082
F/84 ADD 794.6 713.7 89.9 0.898 0.113
PET-CSF+
M/77 aMCI 446.4 612.8 100.6 1.373 0.225
F/63 aMCI 548.4 391.3 57.9 0.714 0.106
F/69 Clinically diagnosed as AD as memory impairment was the main symptom, but the diagnosis was changed to bvFTD with detailed clinical interview along with negative amyloid PET 274.1 628.3 97.8 2.293 0.335
F/55 Clinically diagnosed as AD. However, the diagnosis was changed to bvFTD after the review of clinical course along with negative amyloid PET, and positive flortaucipir (tau) PET that demonstrated increased uptakes in both frontotemporal areas. 337.0 408.4 61.1 1.212 0.181
M/82 Clinically diagnosed as AD, but found to have minimal amount of chronic SDH. 486.7 1,529.2 24.1 3.142 0.050

aMCI = amnestic mild cognitive impairment, ADD = Alzheimer's disease dementia, APOE4 = apolipoprotein E4 gene, PET = positron emission tomography, CSF = cerebrospinal fluid, Aβ42 = beta amyloid 1-42, T-tau = total tau, P-tau = phosphorylated tau, bvFTD = behavioral variant frontotemporal dementia, SDH = subdural hemorrhage.